{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-020031","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.932686+00:00","generated_at":"2026-06-01T23:37:14.343463+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biofrontera Q1 revenue down 9% to $7.9M; net loss $10.4M; Ameluz license renegotiated","bullets":["Q1 revenue $7.9M, down 9% YoY from $8.7M due to Change Healthcare data breach reimbursement issues.","Net loss $10.4M ($2.88 per share) vs $7.5M ($5.60 per share) in prior year; loss per share improved due to share count increase.","Cash $3.8M at quarter end vs $1.3M at Dec 31, 2023; raised $8M via preferred placement plus $8M via warrant exercises.","Renegotiated Ameluz transfer price to 25% for 2024-2025 (down from 40-50%) and will assume US clinical trial management from June 1.","FDA accepted sNDA for Ameluz dosage from 1 to 3 tubes; final decision expected by Oct 4, 2024; new RhodoLED XL lamp sales expected Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-020031","json":"https://secwatch.observer/filing/0001493152-24-020031.json","markdown":"https://secwatch.observer/filing/0001493152-24-020031.md","text":"https://secwatch.observer/filing/0001493152-24-020031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224020031/0001493152-24-020031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224020031/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:37:14.343463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"300ea42c7480a2ee52cf5539019956b0dc21fb0b","claim":"Biofrontera Inc. reported the three months ended March 31, 2024 results: revenue $7.9 million, net income $10.4 million, or $(2.88) per share, EPS $(2.88) per share.","evidence_excerpt":"2024 and provided a business update. Highlights from the first quarter of 2024 and subsequent weeks included the following: ● Total revenues for the first quarter of 2024 were $7.9 million, a 9% decrease from the same period of the prior year primarily driven by reimbursement headwinds our customers experienced due to the Change Healthcare data breach ● Cash and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224020031/0001493152-24-020031-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$7.9 million"},{"label":"Net income","value":"$10.4 million, or $(2.88) per share"},{"label":"EPS","value":"$(2.88) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}